Induction immunotherapy for advanced non-small cell lung cancer patients without curative options
Prospective Trial of Immunotherapy Prior to Resection, Definitive Chemo-radiotherapy, or Palliative Therapy in Patients With Locally Advanced or Oligometastatic Non-small Cell Lung Cancer Without a Primary Curative Option
This study is testing if a new type of immunotherapy can help people with advanced non-small cell lung cancer who can't have surgery or other curative treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Klinikum Esslingen Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Esslingen am Neckar) |
| Trial ID | NCT04926584 on ClinicalTrials.gov |
What this trial studies
This study enrolls patients with locally advanced or oligometastatic non-small cell lung cancer (NSCLC) who cannot undergo curative treatment due to large tumor size or functional limitations. Patients receive induction immunotherapy as recommended by a multidisciplinary tumor board, followed by radiological assessment of their response. Depending on the evaluation, patients may then receive either definitive curative treatment or palliative care. The goal is to explore the effectiveness of immunotherapy in this challenging patient population.
Who should consider this trial
Good fit: Ideal candidates are patients with newly diagnosed, histologically or cytologically proven stage III - IVA NSCLC who are not eligible for curative treatment.
Not a fit: Patients with resectable tumors or those for whom definitive chemoradiotherapy is feasible may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new treatment option for patients with advanced NSCLC who currently have limited curative options.
How similar studies have performed: While there have been studies on immunotherapy for NSCLC, this specific approach in the context of oligometastatic disease without curative options is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * newly diagnosed NSCLC * histologically or cytologically proven * stage III - IVA (oligometastatic) by complete staging * ECOG 0-2 * life expectancy 3 months * ability to provide written informed consent Exclusion Criteria: * primary resectability * primary definitive chemoradiotherapy feasible
Where this trial is running
Esslingen am Neckar
- Klinikum Esslingen — Esslingen am Neckar, Germany (Recruiting)
Study contacts
- Study coordinator: Martin Faehling, MD, MSc
- Email: m.faehling@klinikum-esslingen.de
- Phone: +49711310382411
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.